



REFERENCES

1. United Nations. United Nations High Level meeting on AIDS [online] 2011, June 10 [cited 2011, June 22] Available from: <http://www.un.org/en/ga/aidsmeeting2011/documents.shtml>
2. AIDS at 30: Nations at the crossroads. [Online] UNAIDS, May 2011. [cited 20 June 2011] Available from: <http://www.unaids.org/unaidresources/aidsat30/aids-at-30.pdf>
3. Ford N, Wilson D, Costa Chaves G, Lotrowska M, Kijtiwatchakul K. Sustaining access to antiretroviral therapy in the less developed world: lessons from Brazil and Thailand. *AIDS* 2007 Jul; 21 Suppl 4: S21-9.
4. WHO, UNAIDS, UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2008. [Online]. Geneva: WHO; 2008. Available from: http://www.who.int/hiv/pub/towards_universal_access_report_2008.pdf
5. Ena J, Leach A, Nguyen P. Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials. *HIV Med*. 2008 Oct; 9(9): 747-56. [cited 2010 May 22]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18218001>
6. World Health Organization. Antiretroviral therapy for HIV infection in Adults and Adolescents: Recommendations for a Public Health Approach – 2010 revision. [Online] Geneva, 2010 [cited 2011, June 16]. <http://www.who.int/hiv/pub/arv/adult2010/en/index.html>
7. WHO. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. [Online]. Geneva: WHO; 2009 Nov. [cited 2010, May 20]. Available from: http://www.who.int/hiv/pub/arv/rapid_advice_art.pdf
8. European Medicines Agency. Outcome of a renewal procedure. Questions and answers on the review of Zerit (stavudine). [Online]. 2011. [Cited 2011 Apr 8] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/human/000110/WC500102227.pdf
9. Initiation of Antiretroviral Treatment Protects Uninfected Sexual Partners from HIV Infection (HPTN Study 052). [Online] HIV Prevention Trials Network, 2011, May 12. [cited 20 June 2011] Available from: http://www.hptn.org/web%20documents/PressReleases/HPTN052PressReleaseFINAL5_12_118am.pdf
10. Lynch S, Ford N. Getting ahead of the wave: Lessons for the next decade of the AIDS response. [Online] Geneva, Medecins Sans Frontieres; 2011, May [cited 2011, June 20] Available from: [http://www.msaccess.org/media-room/press-releases/press-release-detail/?tx_ttnews\[tt_news\]=1688&cHash=d61518513a](http://www.msaccess.org/media-room/press-releases/press-release-detail/?tx_ttnews[tt_news]=1688&cHash=d61518513a)
11. Boulle, A, Van Custem, G, et. Al. Seven year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. *AIDS* 2010, 24:563–572. [2009 October 1]. [cited 2010 May 22].
12. Van Cutsem, G. Treatment failure, access to viral load, and challenges to implementing an improved first-line regimen: MSF experience in Khayelitsha and beyond. The Emergency is not over: Access to Treatment and Challenges of Long Term Survival on Antiretroviral, Cape Town, Cape Town International Convention Centre. International AIDS Conference 2009. 2009 July.
13. Stover J. Forecasting Demand for ARVs 2011-2012. [online] Geneva, Switzerland. 2011, February 15. [cited 2011, June 15] Available from: http://www.who.int/entity/hiv/amds/pfi_forecasting_demand_arvs_j_stover.pdf
14. Verloes R, van't Klooster G, Baert L, et al. TMC 278 long acting – a parenteral nanosuspension formulation that provides sustained clinically relevant plasma concentrations in HIV-negative volunteers. Abstract TUPE0042, presented at the XVII International AIDS Conference, August 3–8, 2008, Mexico City, MX.
15. Eron J, Kumar P, Lazzarin A, et al. DTG in Subjects with HIV Exhibiting RAL Resistance: Functional Monotherapy Results of VIKING Study Cohort II. 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011). Boston. February 27-March 2, 2011. Abstract 151LB.
16. Waning B, Diedrichsen E, Moon S. A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries. *Journal of the International AIDS Society* 2010, 13:35
17. World Health Organization. Prequalification programme. Available from: www.who.int/prequal
18. President's Emergency Plan for AIDS Relief: Approved and Tentatively Approved Antiretrovirals in Association with the President's Emergency Plan. [Online] US FDA, 2011, June 2 (updated). [cited 2011, June 20]. Available from: <http://www.fda.gov/InternationalPrograms/FDABeyondOurBordersForeignOffices/AsiaandAfrica/ucm119231.htm>
19. Smith, Davey M, and Robert T Schooley. "Running with scissors: using antiretroviral therapy without monitoring viral load." *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America* 46, no. 10 (May 2008): 1598-600. [online] 2008, May. [cited 2011, June 22] Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18419496>
20. U.S. Food and Drug Administration. Drugs@FDA: FDA approved drug products [Online]. [2010] [cited 2010 May 20]. Available from: <http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm?CFID=40051336&CFTOKEN=9f146133c97ab568-8BF2C44A-9DC5-2DCC-39FAD9CA8F3D4F10>
21. Oyomopito, R, M P Lee, P Phanuphak, P L Lim, R Ditangco, J Zhou, T Sirisanthana, et al. "Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD)." *HIV medicine* 11, no. 8 (September 2010): 519-29. [Online] 2010, September [cited 2011, June 11] Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2914850&tool=pmc.ncbi&rendertype=abstract>
22. World Health Organization. Antiretroviral Therapy of HIV Infection in Infants and Children – Recommendations for a Public Health Approach – 2010 revision. [online] Geneva, 2010. [cited 2011, June 10] Available from: <http://www.who.int/hiv/pub/paediatric/infants2010/en/index.html>
23. U.S. Food and Drug Administration Drugs@FDA: FDA approved drug products [Online]. [2010?] [cited 2010 May 20]. Available from: <http://www.accessdata.fda.gov/scripts/cder/drugsatfda/>
24. World Health Organization. WHO model list of essential medicines. 17th ed. [Online]. Geneva: WHO; 2011 Mar [cited 2011 May 20]. Available from: <http://www.who.int/medicines/publications/essentialmedicines/en/index.html>
25. GlaxoSmithKline Annual Report 2009: GSK is changing. Brentford (UK): GlaxoSmithKline; 2010 Mar. Available from: <http://www.gsk.com/investors/rep09/GSKReport-2009-full.pdf>
26. GlaxoSmithKline. Annual report 2004: new challenges, new thinking. Brentford (UK): GlaxoSmithKline; 2005 Mar. Available from: <http://www.gsk.com/investors/annual-reports-04.htm>
27. GlaxoSmithKline. Annual report 2005: human being. Brentford (UK): GlaxoSmithKline; 2006 Mar. Available from: <http://www.gsk.com/investors/annualreports-05.htm>
28. GlaxoSmithKline. Annual report 2006: a human race. Brentford (UK): GlaxoSmithKline; 2007 Mar. Available from: <http://www.gsk.com/investors/rep06/annual-report-2006.pdf>

- 29.** GlaxoSmithKline. Annual report 2007: answering the questions that matter. Brentford (UK): GlaxoSmithKline; 2008 Feb. Available from: <http://www.gsk.com/investors/rep07/annual-report-2007.pdf>
- 30.** GlaxoSmithKline. Annual report 2008: grow, deliver, simplify. Brentford (UK): GlaxoSmithKline; 2009 Mar. Available from: <http://www.gsk.com/investors/rep08/GSKReport-2008-full.pdf>
- 31.** Therapeutic nucleosides. EP0349242 (A2) [Online]. 1990 Jan 3 [cited 2010 May 20]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EP0349242&F=0>
- 32.** Chloropyrimide Intermediates. WO9521161 (A1) [Online]. 1995 Aug 10. [cited 2010 May 20]. Available from: European Patent Office: esp@cenet: http://v3.espacenet.com/publicationDetails/biblio?D=B=EPODOC&adjacent=true&locale=en_EP&F=T=D&date=19950810&CC=WO&NR=9521161A1&KC=A1
- 33.** Carbocyclic nucleoside hemisulfate and its use in treating viral infections. WO9852949 (A1) [Online]. 1998 Nov 26 [cited 2010 May 20]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9852949&F=8&QPN=WO9852949>
- 34.** Pharmaceutical compositions. WO9939691 (A2) [Online]. 1998 Aug 12 [cited 2010 May 20]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9939691&F=0&QPN=WO9939691>
- 35.** Australian Government. Department of Health and Ageing. Pharmaceutical benefit scheme Australia [Online] [cited 2011 April 6]. Available from: <http://www.pbs.gov.au/medicine/item/6265R-5602W-6264Q-5601T>
- 36.** Shionogi-ViiV Healthcare. Shionogi-ViiV Healthcare Starts Phase III Trial for "572-Trii" Fixed-Dose Combination HIV Therapy. [Online] London (UK), 2011, February 3. [cited 2011, June 20] Available from: http://www.shionogi.co.jp/ir_en/news/detail_e_110203.pdf
- 37.** Shionogi-ViiV Healthcare. Shionogi-ViiV Healthcare announces commitment to Phase III development program for investigational once-daily HIV integrase inhibitor. [Online] London (UK), 2010, July 21. Available from: http://www.shionogi.co.jp/ir_en/news/detail_e_100721.pdf
- 38.** Amin, Tahir. HIV Drug Patents in China – Full Report. [Online]. 2010 May. [cited 2010 May 20]. Available from: Initiative for Medicines, Access & Knowledge: <http://www.i-mak.org/patent-landscapes/>
- 39.** Initiative for Medicines, Access and Knowledge (I-MAK). Abacavir sulphate [Online]. 2009 [cited 2010 May 20] Available from: <http://www.i-mak.org/abacavir-sulfate/>
- 40.** Patent Number 212734. [Online]. 2007 Dec 14. [cited 2010 May 22]. Available from: Indian Patent Office: http://210.210.88.164/patentgrantedSearch/display/Application.asp?application_number=IN/PCT/2000/193/KOL
- 41.** A bioregional survey and review of first-line treatment failure and second-line paediatric antiretroviral access and use in Asia and Southern Africa. Journal of the International AIDS Society [serial online] 2011. [cited 2011 April 11] 14:7. Available from: <http://www.jiasociety.org/content/14/1/7>
- 42.** Personal communication with Annette Sohn, Director, TREAT Asia, amfAR, The Foundation for AIDS Research Bangkok, Thailand. Price quoted in Malaysian ringgit converted to USD through www.oanda.com [cited 2011 April 11]
- 43.** WHO. Preferred antiretroviral medicines for treating and preventing HIV infection in younger children: report of the WHO paediatric antiretroviral working group, 2007. [Online]. Geneva: WHO; 2008. Available from: <http://www.who.int/hiv/pub/paediatric/antiretroviral/en/index.html>
- 44.** Bristol-Myers Squibb. Annual Report 2010: Significant changes. Significant results. Our biopharma transformation. [Online] Bristol-Myers Squibb; 2011. [cited 2011, June 21] Available from: <http://investor.bms.com/phoenix.zhtml?c=106664&p=irol-reportsannual>
- 45.** Bristol-Myers Squibb. Annual Report 2009: delivering on our commitments. [Online] Bristol-Myers Squibb; 2010. [cited 2011, June 21] Available from: http://thomson.mobular.net/thomson/7/3058/4163/document_0/BMS_AR09.pdf
- 46.** Pujades-Rodríguez M, Balkan S, Arnould L, Brinkhof MA, Calmy A. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. [online] JAMA (Journal of the American Medical Association) 2010 Jul 21; 304(3):303-12. [cited 2011, June 16] Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20639564>
- 47.** Bristol-Myers Squibb. Annual report 2007: BioPharma: the next generation. [Online] Bristol-Myers Squibb; 2008. [cited 2011, June 21]. Available from: <http://www.bmsa.com.au/documents/2007annualreport.pdf>
- 48.** Bristol-Myers Squibb. Bristol-Myers Squibb Company reports financial results for the fourth quarter and 12 months of 2006 and announces EPS guidance for 2007 [Press release]. New York: Bristol-Myers Squibb Company; 2007 Jan 25 [cited 2010 May 21]. Available from: http://www.bms.com/news/press_releases/pages/default.aspx
- 49.** Will once-daily Kaletra be enough to see off the threat of Reyataz? [Article]. Pharmaceutical Business Review. [online] 2005 May 05. [cited 2010 May 20]. Available from: http://www.hospitalpharma.com/features/feature.asp?ROW_ID=591
- 50.** Antivirally active heterocyclic azahexane derivatives. WO9740029 (A1) [Online]. 1997 Oct 30 [cited 2010 May 20]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9740029&F=8&QPN=WO9740029>
- 51.** Bisulfate salt of HIV protease inhibitor. WO9936404 (A1) [Online]. 1999 Jul 22 [cited 2010 May 21]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9936404&F=8&QPN=WO9936404>
- 52.** Process for preparing atazanavir bisulfate and novel forms. WO2005108349 (A2) [Online]. 2005 Nov 17 [cited 2010 May 21]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO2005108349&F=8&QPN=WO2005108349>
- 53.** Personal communication with BMS dated April 8 2011.
- 54.** Antivirally Active Heterocyclic Azahexane Derivatives, WO9740029 [Online], 1997 October 30 [cited 2011 June 14]. Available from: WIPO: http://www.wipo.int/pctdb/en/fetch.jsp?LANG=ENG&DBSELECT=PCT&SERVER_TYPE=19-10&SORT=41311391-KEY&TYPE_FIELD=256&IDB=0&IDOC=210297&C=10&ELEMENT_SET=B&RESULT=1&TOTAL=1&START=1&DISP=25&FORM=SEP-0/HITNUM,B-ENG,DP,MC,AN,PA,ABSUM-ENG&SEARCH_IA=EP1997001860&QUERY=%28WO%2fWO9740029%29+
- 55.** Bisulfate Salt Of HIV Protease Inhibitor, WO9936404 [Online], 1999 June 22 [cited 2011 June 14]. Available from: WIPO: http://www.wipo.int/pctdb/en/fetch.jsp?LANG=ENG&DBSELECT=PCT&SERVER_TYPE=19-10&SORT=41321453-KEY&TYPE_FIELD=256&IDB=0&IDOC=12200&C=10&ELEMENT_SET=B&RESULT=1&TOTAL=1&START=1&DISP=25&FORM=SEP-0/HITNUM,B-ENG,DP,MC,AN,PA,ABSUM-ENG&SEARCH_IA=US1998027382&QUERY=%28WO%2fWO9936404%29
- 56.** Process for Preparing Atazanavir Bisulfate And Novel Forms, WO2005108349 [Online], 2005 November 17 [cited 2011 June 14]. Available from: WIPO: <http://www.wipo.int/patentscope/search/en/WO2005108349>
- 57.** Tableted compositions containing Atazanavir, WO2009002821 [Online], 2008 December 31 [cited 2011 June 14]. Available from: WIPO: <http://www.wipo.int/patentscope/search/en/WO2009002821>
- 58.** Tableted compositions containing Atazanavir, WO2009002829 [Online], 2008 December 31 [cited 2011 June 14]. Available from: WIPO: <http://www.wipo.int/patentscope/search/en/WO2009002829>

- 59.** Tableted compositions containing Atazanavir, WO2009002823 [Online], 2008 December 31 [cited 2011 June 14]. Available from: WIPO: <http://www.wipo.int/patentscope/search/en/WO2009002823>
- 60.** Tableted compositions containing Atazanavir, WO2009002826 [Online], 2008 December 31 [cited 2011 June 14]. Available from: WIPO: <http://www.wipo.int/patentscope/search/en/WO2009002826>
- 61.** Pre-grant opposition filed under section 25(1) of the Indian patents act 1970 against Patent Application No. 805/MAS/1997 [Online] 21 April 1997 [cited 2011 June 14]. Available from: <http://www.scribd.com/doc/57827837/Atazanavir-India-patent-Opposition-8051970>
- 62.** Antivirally Active Heterocyclic Azahexane Derivatives, 805/MAS/1997. [Online]. [cited 2011 June 14] Available from: <http://india.bigpatents.org/apps/117Bu2qG>
- 63.** Patent Opposition. Lawyers Collective: The Third Eye of the Law. [Online]. 2006. [cited 2011 June 14] Available from: <http://www.lawyerscollective.org/amtc/patent-opposition>
- 64.** Letter from India Patent Office on abandonment of Patent application 805/MAS/1997 [Online] 2007 August 16. [cited 2011 June 14] Available from: <http://www.scribd.com/doc/818175/India-atazanavir-abandoned-letter>
- 65.** Heterocyclic azahexane derivatives. 310/CHE/2007. [Online]. 2008 Nov 28. [cited 2011 June 14] Available from: Indian Patent Office: http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=310/CHE/2007
- 66.** Heterocyclic Azahexane Derivatives, 3235/CHE/2008. [Online]. 2008 Dec 22 [cited 2011 June 14] Available from: India Patent Office, Patent Search: <http://www.ipindia.nic.in/ipirs1/patentsearch.htm>
- 67.** Process for preparing Atazanavir Bisulfate and Novel Forms, 6425/DELNP/2006. [Online]. 2007 August 31 [cited 2011 June 14] Available from: India Patent Office: http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=6425/DELNP/2006
- 68.** MSF Press Release: India Rejects Patents for Two Key AIDS Drugs [Online] 2011 January 7, Available from: MSF Campaign for Access to Essential Medicines http://www.msfaccess.org/media-room/press-releases/press-release-detail/?tx_ttnews%5Btt_news%5D=1662&cHash=957225c137
- 69.** Process for preparing Atazanavir Bisulfate and Novel Forms, 2933/DELNP/2009. [Online] 2009 December 25 [cited 2011 June 14] Available from: India Patent Office: http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=2933/DELNP/2009
- 70.** Tableted Compositions Containing Atazanavir, 8524/DELNP/2009. [Online]. [cited 2011 June 14]. Available from: Indian Patent Office: [http://124.124.220.66/patentpublishedsearch/\(X\(1\)S\(1dp04j45etg53i55xfxsobao\)\)/publishApplicationNumber.aspx?application_number=8524/DELNP/2009&AspxAutoDetectCookieSupport=1](http://124.124.220.66/patentpublishedsearch/(X(1)S(1dp04j45etg53i55xfxsobao))/publishApplicationNumber.aspx?application_number=8524/DELNP/2009&AspxAutoDetectCookieSupport=1)
- 71.** Tableted Compositions Containing Atazanavir, 8332/DELNP/2009. [Online]. [cited 2011 June 14]. Available from: Indian Patent Office: http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=8332/DELNP/2009&AspxAutoDetectCookieSupport=1
- 72.** Tableted Compositions Containing Atazanavir, 8330/DELNP/2009. [Online]. [cited 2011 June 14]. Available from: Indian Patent Office: http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=8330/DELNP/2009
- 73.** Tableted Compositions Containing Atazanavir, 8328/DELNP/2009. [Online]. [cited 2011 June 14]. Available from: Indian Patent Office http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=8328/DELNP/2009
- 74.** 310/CHE/2007. Indian Patent Information Retrieval System. Office of Controller General of Patents Designs, and Trademarks. [Online] India, 2011, June [cited 2011, June 22] Available from: http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=310/CHE/2007
- 75.** BMS Economic Performance. [Online] 2006 [cited 2010 May 20]. Available from: <http://www.bms.com/>
- 76.** Information provided by Brazilian Department on DSTs/AIDS and Hepatitis (2010). [cited 2010 June 1].
- 77.** Cimieri F. Fiocruz pretende produzir mais dois remédios antiaids (Fiocruz intends to produce two more AIDS drugs) Estado de São Paulo 2009 Feb 17. Available from: http://www.estadao.com.br/estadaodehoje/20090217/not_imp325004,0.php
- 78.** Formenti L. Pacientes com HIV voltam a sofrer com desabastecimento de remédios (HIV patients suffer again with medicines shortages) Estado de São Paulo 2011 Mar 17. Available from: http://www.estadao.com.br/estadaodehoje/20110317/not_imp693049,0.php
- 79.** Working Group on Intellectual Property GTPI/Rebrip [Online]. 2011 Apr 4. Available from: <http://www.deolhonaspontes.org.br/media/file/Notas%20GTPI%20-%202011/Carta%20sobre%20desabastecimento%20do%20Atazanavir.pdf>
- 80.** Com PPPs, governo nacionaliza produção de mais 4 remédios (Through PPPs, government nationalizes the production of four more medicines). Valor Economico 2011 Apr 5. Available from: <http://www.interfarma.org.br/site2/index.php/artigos-e-noticias/clipping-do-setor/2416-com-ppps-governo-nacionaliza-producao-de-mais-4-remedios>
- 81.** Working Group on Intellectual Property GTPI/Rebrip [Online]. 2011 Apr 19. Available from: http://www.deolhonaspontes.org.br/media/file/Notas%20GTPI%20-%202011/Carta%20GTPI_Preocupa%20C3%A7%C3%B5es.pdf
- 82.** Information provided by Brazilian Department on DSTs/AIDS and Hepatitis (April 2011).
- 83.** Tibotec Therapeutics, Division of Centocor Ortho Biotech Products. Full product information: prezista (darunavir) tablet. Raritan (NJ): Tibotec Therapeutics; 2006. Available from: http://www.prezista.com/prezista/full_prescribing_information.html
- 84.** Johnson and Johnson Annual Report 2010. Celebrating 125 years. [Online] Johnson and Johnson, 2010. [cited 2011, June 16] Available from: <http://www.investor.jnj.com/2010annualreport/pdf/2010-annual-report.pdf>
- 85.** Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors. WO9404492 (A1) [Online]. 1994 Mar 3 [cited 2010 May 20]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9404492&F=1&QPN=WO9404492>
- 86.** Multi-drug resistant retroviral protease inhibitors and associated methods. WO9967254 (A2) [Online]. 1999 Dec 29 [cited 2010 May 20]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9967254&F=0&QPN=WO9967254>
- 87.** Thomson Reuters. Current Patents Gazette, [Online]. 2007, Week 25. [cited 2010 May 22]. Available from: http://thomsonreuters.com/products_services/science/science_products/a-z/current_patents_gazette
- 88.** Tibotec Pharmaceuticals. Tibotec and Emcure Collaborate. [Press Release]. 2008 Dec 3. [cited 2010 May 20]. Available from: http://www.tibotec.com/news/detail.jhtml?action=view&itemname=news_56
- 89.** Australian Government. Department of Health and Ageing. Pharmaceutical benefit scheme Australia [Online] [cited 2011 Apr 6]. Available from: <http://www.pbs.gov.au/medicine/item/5652L-9616D>. Conversion into US\$ from www.oanda.com [Online] [cited 2011 Apr 6]

- 90.** Hydroxyethylamino Sulfonamides useful as Retroviral Protease Inhibitors, WO/1994/004492 [Online], 1994 March 30 [cited 2011 June 15]. Available from: WIPO: [http://124.124.220.66/patentpublishedsearch/\(X\(1\)S\(unyb3uippgsajgysvqwdzp45\)\)/publishApplicationNumber.aspx?application_number=3598/DELNP/2004&AspxAutoDetectCookieSupport=1](http://www.wipo.int/pctdb/en/fetch.jsp?LANG=ENG&DBSELECT=PCT&SERVER_TYPE=19-10&SORT=41315509-KEY&TYPE_FIELD=256&IDB=0&IDOC=1117913&C=10&ELEMENT_SET=B&RESULT=1&TOTAL=1&START=1&DISP=25&FORM=SEP-0/HITNUM,B-ENG,DP,MC,AN,PA,ABSUM-ENG&SEARCH_IA=US1993007814&QUERY=%28WO%2fWO9404492%29+, WO9404492</p>
<p>91. Pseudopolymorphic forms of a HIV Protease Inhibitor, 3598/DELNP/2004 [Online], 2008 January 1 [cited 2011 June 15] Available from: India Patent Office: <a href=)
- 92.** Methods for the preparation of (3R,3AS,6AR) hexahydro-furo [2,3-B] Furan-3-OL, 5301/DELNP/2006 [Online], 2007 August 03 [cited 2011 June 15] Available from: India Patent Office: http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=5301/DELNP/2006&AspxAutoDetectCookieSupport=1
- 93.** Combination of Cytochrome P450 Dependent Protease Inhibitors, 1647/DELNP/2004 [Online], 2007 November 30 [cited 2011 June 15] Available from: India Patent Office: http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=1647/DELNP/2004
- 94.** Combination of anti-HIV Reverse Transcriptase and Protease Inhibitors, 7958/DELNP/2006 [Online] 2007 April 27 [cited 2011 June 15] Available from: India Patent Office: http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=7958/DELNP/2006
- 95.** Rejection Decision of application for Patent no. 3598/ DELNP/ 2004 [Online] 2009 July 6 [cited 2011 June 15] Available from: India Patent Office <http://ipindiaonline.gov.in/decision/3598-%20DELNP-%202004-281/3598-delnp-2004.pdf>
- 96.** Rejection Decision of application for Patent no. 1647/DELNP/2000 [Online] 2009 March 29 [cited 2011 June 15] Available from: <http://ipindiaonline.gov.in/decision/1647-DELNP-2000-284/1647-del-2004.pdf>
- 97.** Application No. 7958/DELNP/2006 Abandoned U/S 21(1) [Online] 2007 April 27 [cited 2011 June 15] Available from: India Patent Office, Patent Search: <http://www.ipindia.nic.in/ipirs1/patentsearch.htm>
- 98.** Combination of Cytochrome p450 dependent Protease Inhibitors, 2221/DELNP/2008 [Online] 2008 April 25 [cited 2011 June 15] Available from: India Patent Office: http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=2221/DELNP/2008
- 99.** Pascualone F. Bristol-Myers Squibb clarification on didanosine supply. The Lancet [serial online] 2010 [cited 2011 April 11]; 376(9746): 1054. Available from: [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(10\)61488-2/fulltext](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61488-2/fulltext)
- 100.** Calmy, Alexandra, Nathan Ford, Bernard Hirschel, S.J. Reynolds, Lut Lynen, Eric Goemaere, F.G. de la Vega, Luc Perrin, and William Rodriguez. "HIV Viral Load Monitoring in Resource-Limited Regions: Optional or Necessary?" Clinical Infectious Diseases 44, no. 1 (2007): 128. <http://cid.oxfordjournals.org/content/44/1/128.short>.
- 101.** Enteric Coated Pharmaceutical composition and Method of Manufacturing. WO 9961002 (A1). [Online]. 1999 Dec 2. [cited 2010 May 20]. Available from: European Patent Office: esp@cenet http://v3.espacenet.com/publicationDetails/biblio?D=B=EPODOC&adjacent=true&locale=en_EP&F=T=D&date=19991202&CC=WO&NR=9961002A1&KC=A1
- 102.** Australian Government. Department of Health and Ageing. Pharmaceutical benefit scheme Australia [Online] [cited 2011 Apr 6]. Available from: <http://www.pbs.gov.au/medicine/item/5666F-6301P>. Conversion into US\$ from www.oanda.com [Online] [cited 2011 Apr 6]
- 103.** Bristol-Myers Squibb. Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community. [Press Release]. New York (NY): BMS; 2007 Dec 5. [cited 2010 May 20]. Available from: http://www.bms.com/news/press_releases/pages/default.aspx
- 104.** Kamal-Yanni M, Nichols K, Tallah E, Otwoma N. Open letter to Lamberto Andreotti, Chief Executive Officer, Bristol-Myers Squibb. The Lancet [serial online] 2010 [cited 2011 April 11]; 375(9733):2213 Available from: [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(10\)60940-3/fulltext](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60940-3/fulltext)
- 105.** WHO Note to National AIDS Programmes, procurement agents and stakeholders on the potential setback of paediatric ddI 25mg and 50mg biffered tablets. 16 July 2010. http://www.who.int/hiv/who_note_ddi_11.pdf
- 106.** Personal communication with BMS dated 8 April 2011.
- 107.** Pinheiro E, et al. Examining the production costs of antiretroviral drugs. [Online] Aids Intern Soc Journal, volume 20 – Issue 13, 2006 Aug 22. Available from: http://journals.lww.com/aidsonline/Abstract/2006/08220/Examining_the_production_costs_of_antiretroviral.8.aspx
- 108.** US FDA, 2010, January. [cited 2011, June 20] Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020156s046lbl.pdf
- 109.** Pascualone F. Bristol-Myers Squibb clarification on didanosine supply. The Lancet [serial online] 2010 [cited 2011 April 11]; 376(9746): 1054. Available from: [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(10\)61488-2/fulltext](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61488-2/fulltext)
- 110.** MSF Campaign for Access to Essential Medicines. 2007: save the pharmacy of the developing world! [Online]. 2009 Jan [cited 2010 May 20]. Available from: <http://www.msaccess.org/main/accesspatents/introduction-to-access-and-patents/milestones/2007-save-the-pharmacy-of-the-developing-world/>
- 111.** Bristol-Myers Squibb. Annual Report 2010: Significant changes. Significant results. Our biopharma transformation. Bristol-Myers Squibb; 2010. Available from: <http://investor.bms.com/phoenix.zhtml?c=106664&p=irol-reportsannual>
- 112.** Bristol-Myers Squibb. Annual Report 2009: delivering on our commitments. Bristol-Myers Squibb; 2010. Available from: http://thomson.mobular.net/thomson/7/3058/4163/document_0/BMS_AR09.pdf
- 113.** Bristol-Myers Squibb. Financial reporting: 2008-2009 financial summary: Bristol-Myers Squibb company worldwide net sales from continuing operations by product quarterly sales trend analysis [Online]. [2009?]. [cited 2010 May 22]. Available from: http://www.bms.com/Documents/investors/product_sales_2009.pdf
- 114.** Bristol-Myers Squibb. Financial results for the 4th quarter and 12 months of 2006 and announces EPS guidance for 2007. [Online]. 25 Jan 2007. [cited 2010 May 22]. Available from: http://www.accessmylibrary.com/coms2/summary_0286-29334362_ITM
- 115.** Bristol-Myers Squibb. Annual report 2005: every hour, every place. Bristol-Myers Squibb; 2006. Available from: http://library.corporate-ir.net/library/10/106/106664/items/189260/BMY_AR_05.pdf
- 116.** Bristol-Myers Squibb. Annual report 2008: BioPharma: our strategy in action. Bristol-Myers Squibb; 2009. Available from: http://library.corporateir.net/library/10/106/106664/items/329615/89F48B26-8E28-4566-8F26-AA9133B83124/BMS_AR08.pdf
- 117.** Benzoxazinones as inhibitors of HIV reverse transcriptase. CA2101572 (A1) [Online]. 1994 Feb 8 [cited 2010 May 20]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=CA2101572&F=0&RPN=WO9403440&DOC=deb45b02a96924db95500b c28a42e9b960>
- 118.** Process for the Crystallization of a Reverse Transcriptase Inhibitor Using an Anti-Solvent. WO 9833782 (A1) [Online]. 1998 Aug 6. [cited 2010 May 22]. Available from: European Patent Office: esp@cenet:

- http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=19980806&CC=WO&NR=9833782A1&KC=A1
- 119.** Crystalline efavirenz. WO9964405 (A1) [Online]. 1999 Dec 16 [cited 2010 May 20]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9964405&F=8&QPN=W09964405>
- 120.** Patent Opposition. Lawyers Collective: The Third Eye of the Law. <http://www.lawyerscollective.org/amtc/patentopposition>
- 121.** Compositions and methods for combination antiviral therapy. WO/2004/064845 [Online]. 2004 Aug 5 [cited 2010 May 22]. Available from: WIPO: <http://www.wipo.int/pctdb/en/wo.jsp?wo=2004064845>
- 122.** Decision in the Matter of an application for Patent no. 3383/DELNP/2005 – Gilead Sciences vs Cipla. [Online] Gopakumar Nair Associates, India, 2009, March 25 [cited 2011, June 16] Available from: <http://www.gnaipr.com/CaseLaws/3383DELNP2005.pdf>
- 123.** Stable fixed-dose unitary formulations containing tenofovir, A surfactant, efavirenz and emtricitabine. WO/2006/135933 [Online]. 2006 Dec 21 [cited 2010 May 22]. Available from: WIPO: <http://www.wipo.int/pctdb/en/wo.jsp?wo=2006135933>
- 124.** Thailand. Ministry of Public Health and National Health Security Office. Facts and evidences on the 10 burning issues related to the Government use of patents on three patented essential drugs in Thailand: document to support strengthening of social wisdom on the issue of drug patent. [online] Ministry of Public Health and National Health Security; 2007. [cited 2011, June 20] Available from: <http://www.moph.go.th/hot/White%20Paper%20CL-EN.pdf>
- 125.** Personal communication with Kannikar Kijtiwachakul, MSF Thailand. Price quoted in Thai Baht converted to US\$ through www.oanda.com [cited 2009 Sep 21].
- 126.** Brazil. Ministério da Saúde. Departamento de DST, Aids e Hepatites Virais. Brasil declara o medicamento Efavirenz de interesse público [Press release]. Brasília: Departamento de DST, Aids e Hepatites Virais; 2007 Apr 25 [cited 2010 May 22]. Available from: <http://www.aids.gov.br/data/Pages/LUMISE77B47C8ITEMID252C EA75915C48019A65E5039AFB9560PTBRIE.htm>
- 127.** Treatment Action Campaign. TAC complaint increases access to efavirenz: MSD finally agrees to grant licences on reasonable terms [Online]. 2008 Jun 1 [cited 2010 May 22]. Available from: <http://www.tac.org.za/community/node/2329>
- 128.** Gilead Sciences. Form 10-K. Foster City (CA): Gilead Sciences, Inc.; 2011 Feb 28. [cited 2011 Apr 6]. Available from: <http://phx.corporate-ir.net/External.File?item=UGFYZW50SUQ9ODM2NDJ8Q2hpbGRJRDR0tMXxUeXB IPTM=&t=1>
- 129.** Gilead Sciences. Gilead Sciences Announces Record Fourth Quarter and Full Year 2009 Financial Results. [Press Release]. Foster City (CA): Gilead Sciences, Inc.; 2010 Jan 26. [cited 2010 May 22]. Available from: http://www.gilead.com/pr_1379225
- 130.** Gilead Sciences. 2006 Form 10-K: annual report which provides a comprehensive overview of the company for the past year. Delaware: Gilead Sciences Incorporated; 2007 [cited 2010 May 22]. Available from: <http://www.gilead.com/pdf/GILEADSCIENCES10K.pdf>
- 131.** Gilead Sciences. Gilead Sciences announces fourth quarter and full year 2007 financial results [Press release]. Foster City (CA): Gilead Sciences, Inc.; 2008 Jan 23 [cited 2010 May 22]. Available from: http://www.gilead.com/pr_1099304
- 132.** Gilead Sciences. Gilead Sciences announces fourth quarter and full year 2008 financial results [Press release]. Foster City (CA): Gilead Sciences, Inc.; 2009 Jan 27 [cited 2010 May 22]. Available from: http://www.gilead.com/pr_1248887
- 133.** Substituted -1,3-oxathiolanes with antiviral properties. EP0382526 (A2) [Online]. 1990 August 16 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EP0382526&F=0>
- 134.** Gazette Journal, Thomson Reuters Science. [Online] 2002. Available from: http://scientific.thomsonreuters.com/media/cd/journals/gazettenews/2002/CPG_News_0224.pdf
- 135.** Method and compositions for the synthesis of BCH-189 and related compounds. WO9111186 (A1) [Online]. 1991 August 8 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9111186&F=0&QPN=WO9111186>
- 136.** Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane. WO9214743 (A2) [Online]. 1992 Sep 3 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9214743&F=8&QPN=WO9214743>
- 137.** Gilead Sciences. Gilead Sciences and Royalty Pharma announce \$525 million agreement with Emory University to purchase royalty interest for emtricitabine [Press release]. Foster City (CA): Gilead Sciences, Inc.; 2005 Jul 18 [cited 2010 May 22]. Available from: http://www.gilead.com/pr_731707
- 138.** Knowledge Ecology International. [Online]. [cited 2010 May 22]. Available from: http://www.keionline.org/index.php?option=com_content&task=view&id=23&Itemid=5
- 139.** Gilead Sciences. Partnerships [Online]. 2010 [cited 2010 May 22]. Available from: http://www.gilead.com/access_partnerships
- 140.** Emtriva (emtricitabine) capsules product sheet. [Online] Gilead Sciences, 2007, June. [cited 2011, June 20] Available from http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021500s010,021896s004lbl.pdf
- 141.** Product Information: Fuzeon, enfuvirtide for injection. Roche Laboratories Inc. & Trimeris Inc. 2007.
- 142.** Synthetic peptide inhibitors of HIV transmission. WO9428920 (A1) [Online]. 1994 Dec 22 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9428920&F=0&QPN=WO9428920>
- 143.** Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome. EP0181150 (A1) [Online]. 1986 May 14 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EP0181150&F=1&QPN=EP0181150&OREQ=0>
- 144.** Thomson Reuters. Current Patents Gazette, [Online]. 2006, Week 13. [cited 2010 May 22]. Available from: http://thomsonreuters.com/products_services/science/science_products/a-z/current_patents_gazette
- 145.** Australian Government. Department of Health and Ageing. Pharmaceutical benefit scheme Australia [Online] [cited 2011 Apr 7]. Available from: <http://www.pbs.gov.au/medicine/item/5710M-6455R>. Conversion into US\$ from www.oanda.com [Online] [cited 2011 Apr 6].
- 146.** Methods and Composition for Peptide Synthesis. [Online]. 1999 Sept 30. [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_V3&FT=D&date=19990930&CC=WO&NR=9948513A1&KC=A1
- 147.** Information provided by Brazilian Department on DSTs/AIDS and Hepatitis (June 2011).
- 148.** Highlights of prescribing information, Fuzeon (enfuvirtide). US Food and Drug Administration. [cited 2011, June 16] Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021481s020lbl.pdf
- 149.** Product information: INTELENCE oral tablets, etravirine oral tablets. Tibotec Therapeutics, Division of Ortho Biotech Products, Raritan, NJ, 2008.

- 150.** HIV replication inhibiting pyrimidines. WO0027825 (A1) [Online]. 2000 May 18 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO0027825&F=0&QPN=WO0027825>
- 151.** Janssen Pharmaceutica. About Janssen: Janssen Pharmaceutica [Online] [cited 2010 May 22]. Available from: http://www.janssenpharmaceutica.be/about_jp_E.asp
- 152.** Tibotec. About Tibotec [Online] [cited 2010 May 22]. Available from: <http://www.tibotec.com/bgdisplay.jhtml?itemname=about>
- 153.** HIV replication inhibiting pyrimidines, Patent No. 204028 [Online] 2007 May 25 [cited 2011 June 15] Available from: India Patent Office: [http://www.ipindiaonline.gov.in/patentgrantedSearch/\(S\(5nvhxi0cpb1ai2hnrzw0tal\)\)/displayApplication.aspx?application_number=IN/PCT/2001/00436/MUM](http://www.ipindiaonline.gov.in/patentgrantedSearch/(S(5nvhxi0cpb1ai2hnrzw0tal))/displayApplication.aspx?application_number=IN/PCT/2001/00436/MUM)
- 154.** HIV Inhibiting 2-(4-Cyanophenyl)-6-Hydroxylaminopyrimidines, 4697/DELNP/2007 [Online] 2007 August 17 [cited 2011 June 15] Available from: India Patent Office: http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=4697/DELNP/2007
- 155.** European Medicines Agency. European Medicines Agency decision of 23 December 2009 on the acceptance of a modification of an agreed paediatric investigation plan for etravirine (Intelence) (EMA-000222-PIP01-08-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended. 2009 Dec 23 [cited 2010 May 22]. Available from: <http://www.ema.europa.eu/pdfs/human/paediatrics/000222-PIP01-08-M01.pdf>
- 156.** Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors. WO9933815 (A1) [Online]. 1999 Jul 8 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9933815&F=1&QPN=WO9933815>
- 157.** Ouyang H. Case study: fosamprenavir: a prodrug of amprenavir. In: Stella VJ, Borchardt RT, Hageman MJ, Oliyai R, Maag Hand Tilley JW. Biotechnology: pharmaceutical aspects. New York: SpringerLink; 2008. Available from: <http://www.springerlink.com/content/p05m154851103010/?p=0eb3f6f80327487a885192b60b204bb8&pi=8>
- 158.** Calcium (3S) Tetrahydro-3-Furanyl(1S,2R)-3-[[4-(Aminophenyl) Sulfonyl] (Isobutyl) Amino]-1-Benzy-2-(Phosphonoxy) Propylcarbamate. WO 0004033 (A1). [Online]. 2000 Jan 27. [cited 2010 May 22]. Available from: http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=20000127&CC=WO&NR=0004033A1&KC=A1
- 159.** Prioritizing second-line antiretroviral drugs for adults and adolescents: a public health approach: report of a WHO working group meeting, WHO HIV Department, Geneva, 21-22 May 2007. Geneva: WHO; 2007. Available from: http://www.who.int/hiv/pub/meetingreports/Second_Line_Antiretroviral.pdf
- 160.** African Intellectual Property Organization. History of OAPI [Online] [cited 2010 May 22]. Available from: <http://www.oapi.wipo.net/en/OAPI/historique.htm>
- 161.** HIV protease inhibitors useful for the treatment of AIDS. WO9309096 (A1) [Online]. 1993 May 13 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9309096&F=8&QPN=WO9309096>
- 162.** Merck and Co. Crixivan (indinavir sulfate): prescribing information. Whitehouse Station (NJ, USA): Merck and Co, Inc. [cited 2010 May 22]. Available from: http://www.merck.com/product/usa/pi_circulars/c/crixivan/crixivan_pi.pdf
- 163.** GlaxoSmithKline Annual Report 2010: Do more, feel better, live longer. Brentford (UK): GlaxoSmithKline; 2011 Mar. Available from: <http://www.gsk.com/investors/rep10/GSK-Annual-Report-2010.pdf>
- 164.** Crystalline oxathiolane derivatives. EP0517145 (A1) [Online]. 1992 Dec 09 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=EP0517145&F=0&RPN=WO9221676&DO C=deb45b02a96922db93500ecb934bf2c269&QPN=WO9221676>
- 165.** Pharmaceutical compositions containing lamivudine. IL131917 (A) [Online]. 2001 Jan 11 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=20010111&CC=IL&NR=131917A&KC=A
- 166.** Abbott. Abbott Reports Double-Digit Sales and Ongoing Earnings Growth in Fourth Quarter; Issues Ongoing Earnings Outlook for 2011. [Press Release]. Abbot Park (IL, USA): 2011 Jan 26. [cited 2011 Apr 7]. Available from: <http://www.abbott.com/PressRelease/2011Jan26.htm>
- 167.** Abbot. Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Issues Strong Earnings Outlook for 2010. [Press Release]. Abbot Park (IL, USA): 2010 Jan 27. [cited 2010 May 22]. Available from: http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0816.htm
- 168.** Abbott Laboratories Highlights from recent Management Meetings, North America Equity Research, 6 July 2005.
- 169.** Abbot. Abbott reports 16.1 percent sales growth in fourth quarter [Press release]. Abbot Park (IL, USA): Abbott; 2008 Jan 23 [cited 2010 May 22]. Available from: http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0568.htm
- 170.** Retroviral protease inhibiting compounds. WO9721685 (A1) [Online]. 1997 Jun 19 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9721685&F=0&QPN=WO9721685>
- 171.** Pharmaceutical composition. WO9822106 (A1) [Online]. 1998 May 28 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9822106&F=1&QPN=WO9822106>
- 172.** Solid pharmaceutical dosage form. WO2005039551 (A2) [Online]. 2005 May 6 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO2005039551&F=0&QPN=WO2005039551>
- 173.** Crystalline pharmaceutical, IN/PCT/2002/01243/MUM A [Online] 2005 March 4 [cited 2011 June 16] Available from: <http://india.bigpatents.org/apps/3gnRsvmV>
- 174.** Polymorph of ritonavir, 1638/MUMNP/2007 [Online] 2007 November 23 [cited 2011 June 16] Available from: India Patent Office [http://124.124.220.66/patentpublishedsearch/\(X\(1\)S\(1g02djmeY4tz5l45bz1m01qd\)\)/publishApplicationNumber.aspx?application_number=1638/MUMNP/2007&AspxAutoDetectCookieSupport=1](http://124.124.220.66/patentpublishedsearch/(X(1)S(1g02djmeY4tz5l45bz1m01qd))/publishApplicationNumber.aspx?application_number=1638/MUMNP/2007&AspxAutoDetectCookieSupport=1)
- 175.** Polymorph of a Pharmaceutical, IN/PCT/2001/00018/MUM [Online] 2001 September 15 [cited 2011 June 16] Available from: <http://india.bigpatents.org/apps/4rHoD3qA>
- 176.** Polymorph of Ritonavir, 676/MUMNP/2007 [Online] 2008 February 15 [cited 2011 June 16] Available from: India Patent Office http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=676/MUMNP/2007
- 177.** Polymorph of Ritonavir, 677/MUMNP/2007 [Online] 2008 February 15 [cited 2011 June 16] Available from: India Patent Office http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=677/MUMNP/2007
- 178.** Solid Pharmaceutical Dosage Form, 339/MUMNP/2006 [Online] 2007 June 29 [cited June 17] Available from: India Patent Office http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=339/MUMNP/2006&AspxAutoDetectCookieSupport=1
- 179.** A Solid Pharmaceutical Dosage Formulation, 6733/DELNP/2007 [Online]

- 2007 September 21 29 [cited June 17]
Available from: <http://india.bigpatents.org/apps/3rvGdPIO>
- 180.** Initiative for Medicines, Access and Knowledge (I-MAK). Lopinavir/ritonavir [Online]. [2009] [cited 2010 May 20]. Available from: <http://www.i-mak.org/lopinavirritonavir/>
- 181.** Rejection Decision for Patent Application no. 339/MUMNP/2006 [Online] 2010 December 30 [cited 2011 June 17] Available from: <http://www.i-mak.org/storage/339.MUMNP.2006.Ddecision%20copy.pdf>
- 182.** Official Letter by Abbott on abandonment of divisional application 726/MUMNP/2009 [Online] 2011 January 29 [cited 2011 June 16] Available from: https://docs.google.com/viewer?a=v&pid=explorer&chrome=true&srcid=0BrFBOOQV_1MM2YyODBJODQtNGNHN500YmNLTgyTtY2MxM2M2ZGE4ZGRh&hl=en&aut hkey=CIShooB&pli=1
- 183.** Patent status of application no. 2474/DELNP/2009 as abandoned [Online] 2009 July 31 [cited 2011 June 16] Available from: India Patent Office: <http://www.ipindia.nic.in/ipirs1/patentsearch.htm>
- 184.** Rejection Decision for Patent Application no. IN/PCT/2002/01243/MUM [Online] 2010 September 27 [cited 2011 June 16] Available from: <http://www.i-mak.org/storage/IPO%20Decision%20IN-PCT-2002-1243-MUM%20Order.pdf>
- 185.** Pre Grant Opposition filed against Polymorph of Ritonavir, 1638/MUMNP/2007 [Online] 2007 November 23 [cited 2011 June 16] Available from: India Patent Office/Patent Search <http://www.ipindia.nic.in/ipirs1/patentsearch.htm>
- 186.** Process and Intermediates for preparing Retroviral Protease Inhibitors, 259/MUMNP/2003 A [Online] 2005 March 4 [cited 2011 June 16] Available from: <http://india.bigpatents.org/apps/2EIDpHs0>
- 187.** Hasenclever L, Lopes R, Chaves GC, Reis R, Vieira M. O instituto de patentes Pipeline e o acesso a medicamentos: aspectos econômicos e jurídicos deletérios à economia da saúde (The pipeline mechanism and Access to medicines: economic and juridical aspects). Rev. Direito Sanit. vol.11 no2 2010 Out. Available from: http://www.revistasusp.sibi.usp.br/scielo.php?pid=S1516-41792010000300007&script=sci_arttext
- 188.** MSF Campaign for Access to Essential Medicines. Are Brazilian Pipeline Patents Constitutional? [Online]. 2010 April 21. [cited 2010 May 20]. Available from: <http://www.msffaccess.org/main/access-patents/are-brazilian-pipeline-patents-constitutional/>
- 189.** Acordo do governo brasileiro com a Abbott frustra expectativas dos brasileiros, afirma Abia (Agreement between the Brazilian government and Abbott frustrates Brazilian citizens expectations, says Abia). Depto DST/AIDS Hep 2005 Jul 13. Available from: <http://www.aids.gov.br/noticia/acordo-do-governo-brasileiro-com-abbott-frustra-expectativas-dos-brasileiros-afirma-abia>
- 190.** Working Group on Intellectual Property GTPI/Rebrip [Online]. 2006. Available from: http://www.patentes.org.br/media/file/Casos/Brasil/acao_civil_publica.PDF
- 191.** Working Group on Intellectual Property GTPI/Rebrip [Online]. 2006. Available from: http://www.patentes.org.br/media/file/Casos/Brasil/decisao_liminar.PDF
- 192.** Working Group on Intellectual Property GTPI/Rebrip [Online]. 2006 Dez 01. Available from: <http://www.deolhonaspentes.org.br/media/file/Subs%C3%ADdio%20Kaletra.pdf>
- 193.** The Patent status database for selected HIV medicines. Medicines Patent Pool [Online]. 2011. [cited 2011, June 16] Available from: <http://www.medicinespatentpool.org/LICENSING/Patent-Status-of-ARVs>
- 194.** WHO. Report of the WHO technical reference group, paediatric HIV/ART care guideline group meeting: WHO Headquarters, Geneva, 10-11 April. Geneva: WHO; 2008. Available from: http://www.who.int/hiv/pub/paediatric/WHO_Paediatric_ART_guideline_rev_mreport_2008.pdf
- 195.** FDA Drug Safety Communication: Serious health problems seen in premature babies given Kaletra (lopinavir/ritonavir) oral solution. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm246002.htm#safety_announcement
- 196.** Product information: Selzentry oral tablets, Maraviroc oral tablets. Pfizer, Inc., NY, 2007.
- 197.** Azabicycloalkanes as CCR5 modulators. WO0038680 (A1) [Online]. 2000 Jul 6 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO0038680&F=1&QPN=WO0038680>
- 198.** Tropane derivatives useful in therapy. WO190106 (A2) [Online]. 2001 Nov 29 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO190106&F=1&QPN=WO190106>
- 199.** Van Roey J, von Schoen-Angerer T, Ford N, Calmy A. How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals. Drug Discov Today 2008 Jul;13(13-14):601-5. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18598916?dopt=Abstract>
- 200.** Patent specification, Patent no IN204132. [online] Indian Patent Office, 2010, Dec 31 [cited 2011, June 20] Available from: <http://www.ipindiaonline.gov.in/patentgrantedSearch/>
- 201.** Singh, K. Natco seeks Pfizer nod for drug clone. [Online] India, The Economic Times, 2011, January 5. [cited 2011, June 21] Available from: <http://m.economicstimes.com/PDAET/articleshow/7220479.cms>
- 202.** African Regional Intellectual Property Organisation. About ARIPO [Online]. 2006 Oct 9 [cited 2010 May 22]. Available from: http://www.aripo.org/index.php?option=com_content&view=article&id=19&Itemid=53
- 203.** African Intellectual Property Organization. History of OAPI. [Online]. [cited 2010 May 2010]. Available from: <http://www.oapi.wipo.net/en/OAPI/historique.htm>
- 204.** Patent specification, Patent no IN211212. [online] Indian Patent Office, 2010, Dec 31 [cited 2011, June 20] Available from: [http://www.ipindiaonline.gov.in/patentgrantedSearch/\(S\(z423in4532a3uyndj4ojihv\)\)/?displayApplication.aspx?application_number=IN/PCT/2002/00923/DEL](http://www.ipindiaonline.gov.in/patentgrantedSearch/(S(z423in4532a3uyndj4ojihv))/?displayApplication.aspx?application_number=IN/PCT/2002/00923/DEL)
- 205.** Patent specification, Patent no IN224374. [online] Indian Patent Office, 2010, Dec 31 [cited 2011, June 20] Available from: [http://www.ipindiaonline.gov.in/patentgrantedSearch/\(S\(lrpn2245xsqyhh55w50uykvu\)\)/?displayApplication.aspx?application_number=5511/DELNP/2005](http://www.ipindiaonline.gov.in/patentgrantedSearch/(S(lrpn2245xsqyhh55w50uykvu))/?displayApplication.aspx?application_number=5511/DELNP/2005)
- 206.** Bedrij C, Finnigan T, Matchett SC. Major developments in the treatment of HIV/AIDS: Biotechnology/pharmaceuticals: HIV/AIDS: industry report, 2005. New York: Griffin; 2005 [cited 2010 May 22]. Available from: <http://www.aethlonmedical.com/pdfs/IndustryReport.pdf>
- 207.** HIV protease inhibitors. WO9509843 (A1) [Online]. 1995 Apr 13 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9509843&F=1&QPN=WO9509843>
- 208.** Roche. Investor update: European licence for Roche HIV drug viracept recommended for re-instatement [Online]. Basel: Roche; 2007 Sep 20 [cited 2010 May 22]. Available from: <http://www.roche.com/inv-update-2007-09-20e>
- 209.** WHO. Prequalification programme: a United Nations Programme managed by WHO [Online] [cited 2010 May 22]. Available from: <http://apps.who.int/prequal/>
- 210.** U.S. Food and Drug Administration. Drugs@FDA: FDA approved drug products [Online]. [2011] [cited 2011 June 14]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020778ap.pdf

- 211.** Boehringer Ingelheim. Annual report 2007. Ingelheim: Boehringer Ingelheim; 2008 [cited 2010 May 22]. Available from: http://www.boehringer-ingelheim.nl/content/dam/internet/opu/nl_NL/documents/downloads/annual_report_2007.pdf
- 212.** Boehringer Ingelheim. Annual report 2004. Ingelheim: Boehringer Ingelheim; 2005. [cited 2010 May 22].
- 213.** Boehringer Ingelheim. Annual report 2005. Ingelheim: Boehringer Ingelheim; 2006 [cited 2010 May 22]. Available from: http://mediapool.boehringer-ingelheim.com/index.php?id=18&tx_mediadb_pi%5Bcat%5D=128&cHash=f3930e00d3
- 214.** Boehringer Ingelheim. Annual report 2006. Ingelheim: Boehringer Ingelheim; 2007 [cited 2010 May 22]. Available from: http://www.boehringer-ingelheim.nl/content/dam/internet/opu/nl_NL/documents/downloads/annual_report_2006.pdf
- 215.** 5,11-Dihydro-6H-dipyrido[3,2-b:2',3'-e] [1,4]diazepines and their use in the prevention or treatment of HIV infection. EP0429987 (A2) [Online]. 1991 Jun 5 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EP0429987&F=8>
- 216.** Pharmaceutical suspension comprising nevirapine hemihydrate. WO9909990 (A1) [Online]. 1999 Mar 4 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9909990&F=0&QPN=W09909990>
- 217.** Extended release formulation of nevirapine. AU2008262031 (A1) [Online]. 2008 Dec 18 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_V3&FT=D&date=20081218&CC=AU&NR=2008262031A1&KC=A1
- 218.** Boehringer Ingelheim. USFDA approves one-pill, once-daily Viramune® XR™ (nevirapine) extended-release tablets for use in combination with other antiretroviral agents for treatment of HIV-1 infection in adults. [Press Release]. Ingelheim am Rhein, (Germany): 2011 March 31. [cited 2011 Apr 7]. Available from: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/31_march_2011_hiv aids.html
- 219.** Lawyers Collective. Patent for Nevirapine Rejected. [Online]. 2007 Aug 31. [cited 2010 May 22]. Available from: <http://www.lawyerscollective.org/amtc/patentopposition/nevirapine>
- 220.** Extended Release Formulation of Nevirapine, WO/2008/154234 [Online] 2008 December 18 [cited 2011 June 18] Available from: WIPO http://www.wipo.int/pctdb/en/fetch.jsp?LANG=ENG&DBSELECT=PCT&SERVER_TYPE=19-10&SORT=41317401-KEY&TYPE_FIELD=256&IDB=0&IDOC=1641915&C=10&ELEMENT_SET=B&RESULT=1&TOTAL=1&START=1&DISP=25&FORM=SEP-0/HITNUM,B-ENG,DP,MC,AN,PA,ABSUM-ENG&SEARCH_IA=US2008065705&QUERY=%28WO%2fWO2008154234%29+
- 221.** Extended Release Formulation Of Nevirapine 4724/DELNP/2009 [Online] 2010 March 5 [Cited 2011 June 20] Available from: India Patent Office [http://124.124.220.66/patentpublishedsearch/\(X\(1\)S\(aqrrvd2vke25s5ulxsuodyvf\)\)/publishApplicationNumber.aspx?application_number=4724/DELNP/2009&AspxAutoDetectCookieSupport=1](http://124.124.220.66/patentpublishedsearch/(X(1)S(aqrrvd2vke25s5ulxsuodyvf))/publishApplicationNumber.aspx?application_number=4724/DELNP/2009&AspxAutoDetectCookieSupport=1)
- 222.** Merck and Co. Isentress (raltegravir) tablets: prescribing information. Whitehouse Station (NJ, USA): Merck and Co, Inc.; 2007 [cited 2010 May 22]. Available from: http://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.pdf
- 223.** Merck and Co. 2010 Form 10K: annual report. Whitehouse Station (NJ, USA): Merck and Co, Inc.; 2011 Feb 28. [cited 2011 Apr 7]. Available from: <http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9ODM1MDV8Q2hpbGRJRDR0tMXxUeXBIPtM=&t=1>
- 224.** Merck and Co. 2009 Form 10K: annual report. Whitehouse Station (NJ, USA): Merck and Co, Inc.; 2010 Mar 1. [cited 2010 May 22]. Available from: http://www.merck.com/finance/annualreport/ar2009/pdf/Merck_form_10-k.pdf
- 225.** Merck and Co. 2008 Form 10-K: annual report. Whitehouse Station (NJ, USA): Merck and Co, Inc.; 2009 [cited 2010 May 22]. Available from: http://media.corporate-ir.net/media_files/irol/73/73184/MRKForm10K2008final.pdf
- 226.** N-Substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase. WO03035077 (A1) [Online]. 2003 May 1 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO03035077&F=0&QPN=WO03035077>
- 227.** Potassium salt of an HIV intergrase inhibitor. WO2006060712 (A2) [Online]. 2006 Jun 8 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO2006060712&F=0&QPN=WO2006060712>
- 228.** Australian Government. Department of Health and Ageing. Pharmaceutical benefit scheme Australia [Online] [cited 2011 May 13]. Available from: [http://www.pbs.gov.au/medicine/item/9629T-9523F_Conversion_into_US\\$%20from%20www.oanda.com](http://www.pbs.gov.au/medicine/item/9629T-9523F_Conversion_into_US$%20from%20www.oanda.com) [Online] [cited 2011 Apr 6]
- 229.** Potassium Salt of an HIV Integrase Inhibitor, WO2006060730 [Online] 2006 June 8 [cited 2011 June 17] Available from: WIPO <http://www.wipo.int/patentscope/search/en/WO2006060730>
- 230.** Potassium Salt of an HIV Integrase Inhibitor, WO2006060712 [Online] 2006 June 8 [cited 2011 June 17] Available from: WIPO <http://www.wipo.int/patentscope/search/en/WO2006060712>
- 231.** N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors of HIV Integrase, WO2003035077 [Online] 2003 May 1 [cited 2011 June 17] Available from: WIPO <http://www.wipo.int/patentscope/search/en/WO2003035077>
- 232.** N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors of HIV Integrase, Patent No. 212400 [Online] 2008 February 15 [cited 2011 June 17] Available from: India Patent Office [http://www.ipindiaonline.gov.in/patentgrantedSearch/\(S\(25ngpj3miuvkn3e5udaa0x55\)\)/displayApplication.aspx?application_number=868/CHENP/2004](http://www.ipindiaonline.gov.in/patentgrantedSearch/(S(25ngpj3miuvkn3e5udaa0x55))/displayApplication.aspx?application_number=868/CHENP/2004)
- 233.** Potassium Salt of an HIV Integrase Inhibitor, 4187/DELNP/2007 [Online] 2007 August 31 [cited 2011 June 17] Available from: India Patent Office http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=4187/DELNP/2007
- 234.** Bonanno L. Governo negocia com Merck transferência de conhecimento para a produção nacional do raltegravir (Government negotiates technology transfer agreement with Merck for national production of raltegravir). Agência de Notícias da AIDS 2010 Set 29. Available from: <http://www.agenciaaids.com.br/site/noticia.asp?id=15713>
- 235.** Working Group on Intellectual Property GTP/Rebrip [Online]. 2011 Apr. Available from: http://www.deolhonaspentes.org.br/media/file/Notas%20GTPi%20-%202011/Carta%20GTPi_Preocupa%C3%A7%C3%B5es.pdf
- 236.** Money Control. Cipla tells Merck your anti-AIDS drug too costly in India. [online] 2011 Apr 07 [cited 2011 June 16] Available from: http://www.moneycontrol.com/news/business/cipla-tells-merck-your-anti-aids-drug-too-costlyindia_533783-1.html
- 237.** U.S. Food and Drug Administration. Drugs@FDA: FDA approved drug products [Online]. 2011 [cited 2011 June 14]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022145s018lbl.pdf
- 238.** Safety and Effectiveness of Raltegravir (MK-0518) in Treatment-Experienced, HIV-Infected Children and Adolescents. [Online] Clinical trials.gov, 2011, June 7. [cited 2011, June 20] Available from: <http://clinicaltrials.gov/show/NCT00485264?order=53>

- 239.** U.S. Food and Drug Administration. Drugs@FDA: FDA approved drug products [Online]. [2011] [cited 2011 May 20]. Available from: <http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm?fuseaction=Search.DrugDetails>
- 240.** Ford N, Lee J, Andrieux-Meyer I, Calmy A. Safety, efficacy and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings. HIV/AIDS – Research and Palliative Care 2011;3 35–44
- 241.** Product information: Edurant oral tablets, rilpivirine oral tablets. Tibotec, Inc., New Jersey, May 2011.
- 242.** Johnson & Johnson. Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment. [Press Release]. Cork, Ireland: 2011 Jan 27. [cited 2011 May 25] Available from: <http://www.investor.jnj.com/releasedetail.cfm?ReleaseID=545920>
- 243.** Ruffell C (cruffell@its.jnj.com) Rilpivirine inclusion in Untangling the Web. E-mail to: Lee J (Janice.lee@msf.org) 2011, May 27.
- 244.** HIV Inhibiting Pyrimidines Derivatives, WO03016306 [Online] 2003 February 27 [cited 2011 June 20] Available from: WIPO http://www.wipo.int/pctdb/en/fetch.jsp?LANG=ENG&DBSELECT=PCT&SERVER_TYPE=19-10&SORT=41324846-KEY&TYPE_FIELD=256&IDB=0&IDOC=270926&C=10&ELEMENT_SET=B&RESULT=1&TOTAL=1&START=1&DISP=25&FORM=SEP-0/HITNUM,B-ENG,DP,MC,AN,PA,ABSUM-ENG&SEARCH_IA=EP2002008953&QUERY=%28WO%2fWO03016306%29+
- 245.** High Accuracy Network Clock Synchronization, WO/2005/002100 [Online] 2005 January 06 [Cited 2011 June 20] Available from: WIPO [http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2005002100&recNum=1&docAn=IB2004051057&queryString=FP:\(wo/200502100\)&maxRec=1](http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2005002100&recNum=1&docAn=IB2004051057&queryString=FP:(wo/200502100)&maxRec=1)
- 246.** HIV replication inhibiting pyrimidines, AP 1610 [Online] 2006 May 08 [cited 2011 June 20] Available from: WIPO http://www.wipo.int/patentscope/search/en/detail.jsf?docId=AP187189&recNum=15&office=&queryString=&prevFilter=%26fq%3DOP%3AAP%26fq%3DPAF_M%3A%2522JANSSEN%2BP HARMACEUTICA%2BN.V.%2522&sortOption=Pub+Date+Desc&maxRec=36
- 247.** HIV inhibiting pyrimidines derivatives, ZA200401159 [Online] 2005 May 12 [Cited 2011 June 20] Available from: <http://www.wikipatents.com/CA-Patent-2537095/combinations-of-a-pyrimidine-containing-nnrti-with-rt-inhibitors>
- 248.** HIV inhibiting pyrimidines derivatives, Application No. CN 02815920 [Online] 2002 August 09 [Cited 2011 June 20] Available from: Chinese Patent Office <http://ip.com/sipoen/1541215>
- 249.** A Pyrimidine Compound Of Formula, Patent No. 222987 [Online] 2008 September 12 [Cited 2011 June 20] Available from: India Patent Office [http://www.ipindiaonline.gov.in/patentgrantedSearch/\(S\(w11oxw554wtfnk34m3l0pe45\)\)/displayApplication.aspx?application_number=00265/DELNP/2004](http://www.ipindiaonline.gov.in/patentgrantedSearch/(S(w11oxw554wtfnk34m3l0pe45))/displayApplication.aspx?application_number=00265/DELNP/2004)
- 250.** HIV Inhibiting Pyrimidines Derivatives, BR0211909 [Online] 2004 August 24 [Cited 2011 June 20] Available from: <http://www.wikipatents.com/CA-Patent-2537095/combinations-of-a-pyrimidine-containing-nnrti-with-rt-inhibitors>
- 251.** Combinations of A Pyrimidine Containing NNTRI With RT Inhibitors, WO2005021001 [Online] 2005 March 10 [Cited 2011 June 20] Available from: WIPO [http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2005021001&recNum=1&docAn=EP2004052028&queryString=FP:\(wo/2005021001\)&maxRec=1](http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2005021001&recNum=1&docAn=EP2004052028&queryString=FP:(wo/2005021001)&maxRec=1)
- 252.** Combinations of A Pyrimidine Containing NNTRI With RT Inhibitors, BRPI0414027 [Online] 2006 October 24 [Cited 2011 June 20] Available from: [http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2005021001&recNum=1&docAn=EP2004052028&queryString=FP:\(wo/2005021001\)&maxRec=1](http://www.wikipatents.com/CA-Patent-2537095/combinations-of-a-pyrimidine-containing-nnrti-with-rt-inhibitors)
- 253.** Combinations of A Pyrimidine Containing NNTRI With RT Inhibitors, 687/DELNP/2006 [Online] 2007 August 17 [Cited 2011 June 20] Available from: India Patent Office http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=687/DELNP/2006&AspxAutoDetectCookieSupport=1
- 254.** New voluntary licences for Rilpivirine, 2011 February 9 [Online] Available from: <http://msf-utw.tumblr.com/post/3199016548/new-voluntary-licences-for-rilpivirine>
- 255.** U.S. Food and Drug Administration. Drugs@FDA: FDA approved drug products [Online]. [2011] [cited 2011 June 14]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf
- 256.** Abbott Laboratories Highlights from Recent Management Meetings, North America Equity Research, 6th July 2005.
- 257.** Protease inhibiting compounds. WO9414436 (A1) [Online]. 1994 Jul 7 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&ID=X=WO9414436&F=1&QPN=WO941443>
- 258.** Polymorph of a pharmaceutical. WO0004016 (A2) [Online]. 2000 Jan 27 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&ID=X=WO0004016&F=1&QPN=WO0004016>
- 259.** Improved Pharmaceutical Formulations. WO 0152821 (A1). [Online]. 2001 Jul 26. [cited 2010 May 20]. Available from: http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&F=T=D&date=20010726&CC=WO&NR=0152821A1&KC=A1
- 260.** Pre Grant Opposition by PLHIV Networks to Patent Application No. IN/PCT/2001/00018/MUM [Online] 2006 August 28 [cited 2011 June 23] Available from: <http://www.i-mak.org/storage/Pregrantopp%20Ritonavir.pdf>
- 261.** Rejection Order of Patent Application No. /PCT/2001/00018/MUM [Online] 2011 April 13 [cited 2011 June 23] Available from: http://www.i-mak.org/storage/IPO%20Decision%20IN.PCT.2001.00018.MUM_us%2015.pdf
- 262.** Official Letter by Abbott on abandonment of divisional applications 676/MUMNP/2007 and 677/MUMNP/2007 [Online] 2011 January 29 [cited 2011 June 16] Available from: https://docs.google.com/viewer?a=v&pid=explorer&chrome=true&srcid=0B_rFBOOQV_1MM2YyODbjODQtNGNhNS00YmNlTgyYtY2MxM2M2ZGE4ZGRh&hl=en&authkey=CISshooB&pli=1
- 263.** Medicines Patent Pool. US National Institutes of Health (NIH) First to Share Patents with Medicines Patent Pool As it Opens for Business. [Online press release] Geneva, 2010, September 30 [cited 2011, June 24] Available from: <http://www.medicinespatentpool.org/content/download/310/2027/version/1/file/Medicines%2BPatent%2BPool%2BNIH%2Blicense%2BPR%2BEMB%2Bfor%2B30%2BSept%2B2010%2BFINAL-1.pdf>
- 264.** Saez, C. Ecuador Grants First Compulsory Licence, For HIV/AIDS Drug. Intellectual Property Watch. [Online]. 2010 Apr 22. [cited 2010 May 22]. Available from: <http://www.ip-watch.org/weblog/2010/04/22/ecuador-grants-firstcompulsory-licence-for-hiv-aids-drug/>.
- 265.** Saez, C. Ecuador To Define Its Compulsory Licence Legislation. Intellectual Property Watch. [Online]. 2009 Nov 23. [cited 2010 May 22]. Available from: <http://www.ip-watch.org/weblog/2009/11/23/ecuador-to-define-its-compulsory-licencelegislation/>
- 266.** Highlights of prescribing information, Norvir (retonavir) [Online] Abbot Laboratories, 2010, April [cited 2011, June 21] Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020659s050,022417s001lbl.pdf
- 267.** Amino acid derivatives. EP0432695 (A2) [Online]. 1991 June 19 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EP0432695&F=1>

- 268.** Saquinavir mesylate oral dosage form. WO2005004836 (A2) [Online]. 2005 Jan 20 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: http://v3.espacenet.com/publicationDetails/biblio?D=EPODOC&adjacent=true&locale=en_V3&F=T=D&date=20050120&CC=WO&NR=200504836A2&KC=A2
- 269.** Pharmaceutical Composition Comprising A Proteinase Inhibitor, Patent No. 200832 [Online] 2007 February 23 [cited 2011 June 16] Available from: India Patent Office [http://www.ipindiaonline.gov.in/patentgrantedSearch/\(S\(ibkxcj55xaf0hkboj5fn355\)\)/displayApplication.aspx?application_number=910/MAS/1996](http://www.ipindiaonline.gov.in/patentgrantedSearch/(S(ibkxcj55xaf0hkboj5fn355))/displayApplication.aspx?application_number=910/MAS/1996)
- 270.** A Process For Preparing A Pharmaceutical Composition Having Enhanced Bioavailability, Patent No. 192899 [Online] 2009 July 24 [cited 2011 June 16] Available from: India Patent Office [http://www.ipindiaonline.gov.in/patentgrantedSearch/\(S\(i53oag55550ptfmbod0anerg\)\)/displayApplication.aspx?application_number=763/MAS/2000](http://www.ipindiaonline.gov.in/patentgrantedSearch/(S(i53oag55550ptfmbod0anerg))/displayApplication.aspx?application_number=763/MAS/2000)
- 271.** Saquina Vir Mesylate Oral Dosage Form, Patent No. 227217 [Online] 2009 February 13 [cited 2011 June 16] Available from: India Patent Office [http://www.ipindiaonline.gov.in/patentgrantedSearch/\(S\(ev4hfq45n4vr1i45jroeeq55\)\)/displayApplication.aspx?application_number=86/CHENP/2006](http://www.ipindiaonline.gov.in/patentgrantedSearch/(S(ev4hfq45n4vr1i45jroeeq55))/displayApplication.aspx?application_number=86/CHENP/2006)
- 272.** WHO. Addendum to 2006 WHO guidelines on antiretroviral therapy for HIV infection in adults and adolescents: new dosage recommendations for stavudine (d4T). Geneva: WHO. Available from: <http://www.who.int/hiv/art/ARTadultsaddendum.pdf>
- 273.** Consumer Project on Technology. Stavudine (d4T) [Online]. [2006?] [cited 2010 May 23]. Available from: <http://www.cptech.org/ip/health/d4T.html>
- 274.** Pharmaceutical composition comprising 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) in treating patients infected with retrovirus. EP0273277 (A2) [Online]. 1988 Jul 7 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EP0273277&F=8>
- 275.** WTO: TRIPS and public health [Online] [cited 2010 May 23]. Available from: http://www.wto.org/english/tratop_e/trips_e/public_health_e.htm
- 276.** Personal communication with BMS dated 8th April 2011.
- 277.** Highlights of prescribing information, Zerit (stavudine) [Online] U.S. Food and Drug Administration, 2010, December [cited 2011, June 21] Available from http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020412s036,020413s028lbl.pdf
- 278.** Gilead Sciences. 2005 Annual report: stepping up. Delaware: Gilead Sciences Inc.; 2006 [cited 2010 May 22]. Available from: <http://ccbn.mobular.net/ccbn/7/1377/1472/print/print.pdf>
- 279.** Gilead Sciences. 2006 Annual report: why we're here. Delaware: Gilead Sciences Inc.; 2007 [cited 2010 May 22]. Available from: http://www.gilead.com/AR2006/GILEAD%20AR06_final.pdf
- 280.** 9-(phosphonylmethoxyalkyl) adenines, the method of preparation and utilization thereof. US4808716 (A) [Online]. 1989 Feb 28 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=US4808716&F=0&RPN=EP0206459&DOC=cca34af1984f08bf7c37f3b37b34dbab52&QPN=EP0206459>
- 281.** Nucleotide analogs. WO9804569 (A1) [Online]. 1998 Feb 5 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9804569&F=8&QPN=W09804569>
- 282.** Nucleotide analog composition and synthesis method. WO9905150 (A1) [Online]. 1999 Feb 4 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9905150&F=8&QPN=WO9905150>
- 283.** Pre Grant Opposition by PLHIV Networks to Patent Application No. 2076/DEL/1997 [Online] 2006 September 5 [cited 2011 June 18] Available from: <http://indianpatentoppositions.blogspot.com/2011/06/td-opposition-and-rejection-order.html>
- 284.** Pre-Grant Opposition by Brazilian NGO and NGO Sahara to Patent Application No. 2076/DEL/1997 [Online] 2007 [cited 2011 June 18] Available from: <http://indianpatentoppositions.blogspot.com/2011/06/td-opposition-and-rejection-order.html>
- 285.** Rejection order of Patent Application No. 2076/DEL/1997 [Online] 2009 July 30 [cited 2011 June 18] Available from: Indian Patent Office <http://ipindiaonline.gov.in/decision/2076-DEL-1997-344/2076-del-1997%20cipla.pdf>
- 286.** Rejection order of Patent Application No. 896/DEL/2002 [Online] 2009 July 30 [cited 2011 June 18] Available from: India Patent Office <http://ipindiaonline.gov.in/decision/896-DEL-2002-340/896-del-2002%20intermed.pdf>
- 287.** Rejection order of Patent Application No. 963/DEL/2002 [Online] 2009 March 9 [cited 2011 June 18] Available from: Indian Patent Office <http://ipindiaonline.gov.in/decision/963-DEL-2002-201/intermed%20decision.pdf>
- 288.** Rejection order of Patent Application No. 3383/DELNP/2005 [Online] 2009 March 25 [Cited 2011 June 18] Available from: India Patent Office <http://ipindiaonline.gov.in/decision/3383-DELNP-2005-285/3383-delnp-2005.pdf>
- 289.** Nucleotide Analogs, 602/DEL/2007 [Divisional Application to 896/DEL/2002] [Online] 2007 August 03 [cited 2011 June 18]. Available from: India Patent Office http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=602/DEL/2007
- 290.** A Compound, 1135/DEL/2007 [Divisional Application to 896/DEL/2002]. [Online]. 2007 August 31. [cited 2011 June 18]. Available from: India Patent Office http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=1135/DEL/2007
- 291.** 6665/DELNP/2008 (Divisional Application to 3383/DELNP/2005). [Online] 2008 October 24 [cited 2011 June 18] Available from: India Patent Office http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=6665/DELNP/2008
- 292.** Working Group on Intellectual Property GTPI/Rebrip [Online]. 2006 Dez 01. Available from: <http://www.deolhonaspates.org.br/media/file/Subs%C3%ADdio%20Tenofovir.pdf>
- 293.** Working Group on Intellectual Property GTPI/Rebrip [Online]. 2009 Nov 05. Available from: <http://www.deolhonaspates.org.br/media/file/Subsidio%20Divisional%20Tenofovir.pdf>
- 294.** I-Mak. Brazilian Patent Office Rejects Gilead Divisional Application for Tenofovir Disoproxil Fumarate 2011 May 18. Available from: <http://www.i-mak.org/i-mak-blog-updates/2011/5/18/brazilian-patent-office-rejects-gileads-divisional-applicati.html>
- 295.** Alves D. Governo passará a fabricar remédio contra Aids que era importado dos EUA (Government Will produce AIDS drug that used to be imported from the US) Correio Braziliense 2011 Feb 10. Available from: http://www.correiobraziliense.com.br/app/noticia/brasil/2011/02/10/interna_brasil,237010/governo-passara-a-fabricar-remedio-contra-aids-que-era-importado-dos-eua.shtml
- 296.** MSF Campaign for Access to Essential Medicines. Neither expeditious, nor a solution: the WTO August 30th decision is unworkable: an illustration through Canada's Jean Chrétien pledge to Africa. Geneva/Montréal: MSF Campaign for Access to Essential Medicines; 2006 Aug. Available from: http://www.msfactess.org/fileadmin/user_upload/medinnov_accesspatents/WTOaugustreport.pdf

- 297.** Department of Health and Human Services. Letter to Dara Wambach, Regulatory Affairs, Gilead Sciences. Supplement Approval. [Letter]. 2010 Mar 24. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/021356s033ltr.pdf
- 298.** U.S. Food and Drug Administration. FDA application search orphan drug designations and approvals [Online]. Available from: <http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm>
- 299.** U.S. Food and Drug Administration. Pediatric drug development and the orphan drug act incentives [Online]. 2009 May 19 [cited 2010 May 23]. Available from: <http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseases/Conditions/HowtoapplyforOrphanProductDesignation/ucm135125.htm>
- 300.** Pyranone compounds useful to treat retroviral infections. WO9530670 (A2) [Online] 1995 Nov 16 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9530670&F=0&QPN=W09530670>
- 301.** Self-emulsifying formulation for lipophilic compounds. WO9906043 (A1) [Online]. 1999 Feb 11 [cited 2010 May 23]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9906043&QPN=WO9906043>
- 302.** Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation. WO9906044 (A1) [Online]. 1999 Nov 11 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9906044&QPN=WO9906044>
- 303.** Brazil. Agencia Nacional de Vigilância Sanitária. Anuência prévia a produtos e processos farmacêuticos: situação dos processos atualizado até 30/11/2009. Patent application no. PI 9507615-8. Available from: http://www.anvisa.gov.br/medicamentos/intelectual/situacao_processos.pdf
- 304.** Novos medicamentos: alternativas para a falência terapêutica (New Medicines: alternatives for therapeutic failure). Cadernos pela vida – Aids, tratamento e ativismo. 2007 Apr;44:4-7. Available from: http://www.aids.org.br/media/File/cadernos/CPV_n44.pdf
- 305.** Vieira, M. Empresas transnacionais européias na América Latina: Estudo de caso de transnacionais farmacêuticas no Brasil. (Transnational European companies at Latin America: Case study of pharmaceutical transnational in Brazil) GTPI/REBRIP – ABIA 2008 Jul. Available from: <http://www.enlazandoalternativas.org/IMG/pdf/5-POR.pdf>
- 306.** Leite F. Empresa deixa de lançar antiAids por discordar de lei de patentes do País (Company refrains from launching and anti-AIDS drug because it disagrees with the patent law of the country). Estado de São Paulo 2008 Jan 19. Available from: <http://www.abin.gov.br/modules/articles/article.php?id=1806>
- 307.** Highlights of prescribing information – Retrovir (zidovudine) [Online] US Food and Drug Administration, 2010, May. [cited 2011, June 16] Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019655s049lbl.pdf
- 308.** India. Government. Ministry of commerce and industry. Patent office, Delhi branch. Decision regarding representation U/S 25 (1) filed by M/S Intermed Labs Pvt. Ltd, Bangalore, (KS) in respect of application No 896/Del/2002 and hearing held on 18/09/2008. 2009 Jul 30 [cited 2010 May 23]. Available from: http://www.i-mak.org/storage/896.DEL.2002_Intermed%20Labs.PDF
- 309.** 9527/DELNP/2007. Indian Patent Information Retrieval System. Office of Controller General of Patents Designs, and Trademarks. [Online] India, 2011, June [cited 2011, June 22] Available from: http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=9527/DELNP/2007
- 310.** 9661/DELNP/2007. Indian Patent Information Retrieval System. Office of Controller General of Patents Designs, and Trademarks. [Online] India, 2011, June [cited 2011, June 22] Available from: http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=9661/DELNP/2007
- 311.** Application Number 9661/DELNP/2007. Stable Fixed-Dose Unitary Formulations Containing tenofovir, a surfactant, efavirenz and emtricitabine. [Online]. 2007 Dec 13. [cited 2010 May 22]. Intellectual Property India. Office of Controller General of Patent, Designs and Trademarks. Available from: http://124.124.220.66/patentpublishedsearch/publishApplicationNumber.aspx?application_number=9661/DELNP/2007
- 312.** Pharmaceutical combination. WO2007068934 (A2) [Online]. 2007 Jun 21 [cited 2010 May 22]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO2007068934&F=0&QPN=WO2007068934>
- 313.** Antiviral combinations containing nucleoside analogs. WO9220344 (A1) [Online]. 1992 Nov 26 [cited 2010 May 23]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9220344&F=0&QPN=W09220344>
- 314.** Pharmaceutical compositions containing lamivudine and zidovudine. WO9818477 (A2) [Online]. 1998 May 7 [cited 2010 May 23]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO9818477&F=0&QPN=WO9818477>
- 315.** Pharmaceutical Composition, 2044/CAL/1997 [Online] 2005 March 11 [Cited 2011 June 20] Available from: India Patent Office/Patent Search <http://ipindia.nic.in/ipirs1/patentsearch.htm>
- 316.** Complete specification of the Application 2044/CAL/1997 [cited 2011 June 20] Available from: <http://crocodoc.com/1RuvPUO>
- 317.** Pre Grant Opposition by PLHIV Networks to Patent Application No. 2044/CAL/1997 [Online] [Cited 2011 June 20] Available from: <http://indianpatentoppositions.blogspot.com/2011/06/azt3tc-opposition.html>
- 318.** Open Letter from GSK promising withdrawal of AZT/3TC FDC [Online] 2006 August 9 [Cited 2011 June 20] Available from: <http://indianpatentoppositions.blogspot.com/2011/06/azt3tc-opposition.html>
- 319.** Pharmaceutical combinations comprising lamivudine, zidovudine and efavirenz for treating viral infections. WO2004089382 (A1) [Online]. 2004 Oct 21 [cited 2010 May 23]. Available from: European Patent Office: esp@cenet: <http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=WO2004089382&F=8&QPN=WO2004089382>
- 320.** Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 49. [cited 2010 May 20]. Available from: <http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>
- 321.** Unnikrishnan C.H. GSK withdraws trizivir patent application 'in public interest'. livemint.com and The Wall Street Journal 2007 Oct 10 [cited 2010 May 23]. Available from: <http://www.livemint.com/2007/10/10005826/GSK-withdraws-Trizivir-patent.html>
- 322.** Apotex. About Apo-Triavir [Online] [cited 2010 May 23]. Available from: <http://www.apotex.com/apotriavir/default.asp>
- 323.** IN240930 – Prodrugs of Aspartyl protease inhibitors [online] [cited 2011, June 23] Available from: [http://www.ipindiaonline.gov.in/patentgrantedSearch/\(S\(3xof14y2uec51p55pf2k4hqk\)\)/displayApplication.aspx?application_number=2210/CAL/1998Z](http://www.ipindiaonline.gov.in/patentgrantedSearch/(S(3xof14y2uec51p55pf2k4hqk))/displayApplication.aspx?application_number=2210/CAL/1998Z)